Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
- PMID: 9631918
- DOI: 10.1097/00007691-199806000-00001
Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
Abstract
Genotypings of two mutations (*2 and *3) in CYP2C19 and the amino acid variants (Arg144/Cys, Tyr358/Cys, Ile359/Leu, and Gly417/Asp) in CYP2C9 were carried out in 140 unrelated Japanese subjects. Thirty-three subjects (23.6%) were genotypically identified as poor metabolizers of CYP2C19, and the allele frequencies of the CYP2C19*2 and CYP2C19*3 were 0.35 and 0.11, respectively. The authors' findings are in agreement with the 18% to 23% prevalence of poor metabolizers in the Japanese populations previously phenotyped. In CYP2C9, all subjects were homozygous (CYP2C9*1) for Arg144, Tyr358, Ile359, and Gly417, except for five subjects (3.6%) who were heterozygous for the Leu359 (CYP2C9*3). The frequencies of Arg144, Tyr358, Ile359, Leu359, and Gly417 variants were 1.0, 1.0, 0.982, 0.018, and 1.0, respectively. The low frequency of the Cys144 allele (CYP2C9*2) in the Japanese population is different from the frequency recently found in British subjects (allele frequency, 0.125 to 0.192). The results suggest that the known interindividual variations in the CYP2C9 sequence among Japanese subjects is small, and that Ile359/Leu is one possible site showing interracial polymorphism.
Similar articles
-
Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.Pharmacogenetics. 1997 Apr;7(2):103-13. doi: 10.1097/00008571-199704000-00003. Pharmacogenetics. 1997. PMID: 9170147
-
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.Clin Pharmacol Ther. 1998 May;63(5):519-28. doi: 10.1016/S0009-9236(98)90103-5. Clin Pharmacol Ther. 1998. PMID: 9630825 Clinical Trial.
-
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.Pharmacogenetics. 1996 Aug;6(4):341-9. doi: 10.1097/00008571-199608000-00007. Pharmacogenetics. 1996. PMID: 8873220
-
[Genetic polymorphism of the CYP2C subfamily].Nihon Yakurigaku Zasshi. 1998 Jul;112(1):15-21. doi: 10.1254/fpj.112.15. Nihon Yakurigaku Zasshi. 1998. PMID: 9755458 Review. Japanese.
-
Pharmacogenetics of CYP2C subfamily in a Japanese population.J Toxicol Sci. 1998 Jul;23 Suppl 2:129-31. doi: 10.2131/jts.23.supplementii_129. J Toxicol Sci. 1998. PMID: 9760448 Review. No abstract available.
Cited by
-
Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.Mol Biol Rep. 2012 Oct;39(10):9423-33. doi: 10.1007/s11033-012-1807-5. Epub 2012 Jun 22. Mol Biol Rep. 2012. PMID: 22722998
-
Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data.BMC Infect Dis. 2019 May 28;19(1):471. doi: 10.1186/s12879-019-4039-7. BMC Infect Dis. 2019. PMID: 31138134 Free PMC article. Clinical Trial.
-
Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.Pharmacogenomics J. 2016 Apr;16(2):113-23. doi: 10.1038/tpj.2015.70. Epub 2015 Oct 27. Pharmacogenomics J. 2016. PMID: 26503820 Review.
-
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective.Can J Infect Dis Med Microbiol. 2014 Nov-Dec;25(6):327-43. doi: 10.1155/2014/340586. Can J Infect Dis Med Microbiol. 2014. PMID: 25587296 Free PMC article. Review.
-
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.Eur J Clin Pharmacol. 2003 Jul;59(3):221-5. doi: 10.1007/s00228-003-0588-0. Epub 2003 May 7. Eur J Clin Pharmacol. 2003. PMID: 12734606 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources